Answers are grounded in this paper and cite their sources.
To tailor regulatory requirements for marketing approval of biosimilars, it is proposed that a biosimilarity report be introduced. This report would integrate quality, pharmacology, immunogenicity, efficacy and safety findings and address how the clinical program could be tailored based on the totality of evidence.
No takes yet. Share an insight, caveat, or question.
Cecil Nick (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: